Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study

Autor:	Robert M. Stoekenbroek, Norman E. Lepor, Frederick J. Raal, Peter L.J. Wijngaard, G. Kees Hovingh, David Kallend
Přispěvatelé:	Experimental Vascular Medicine, Vascular Medicine, ACS - Atherosclerosis & ischemic syndromes, Graduate School, APH - Personalized Medicine, APH - Quality of Care
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	medicine.medical_specialty Low density lipoprotein cholesterol Pilot Projects Familial hypercholesterolemia Proof of Concept Study LDL Hyperlipoproteinemia Type II Inclisiran Physiology (medical) Internal medicine ALN-PCS medicine Humans Molecular Targeted Therapy RNA Small Interfering Ldl cholesterol hypercholesterolemia business.industry Anticholesteremic Agents Homozygote PCSK9 Inhibitors Subtilisin cholesterol Cholesterol LDL Genetic Therapy medicine.disease Proprotein convertase Ezetimibe Endocrinology Treatment Outcome Gene Knockdown Techniques Kexin RNA Interference Hydroxymethylglutaryl-CoA Reductase Inhibitors Proprotein Convertase 9 Cardiology and Cardiovascular Medicine business
Zdroj:	Circulation, 141(22), 1829-1831. Lippincott Williams and Wilkins
ISSN:	0009-7322
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c44db02f50d320f68e3c568903d020b https://doi.org/10.1161/circulationaha.119.044431 Zobrazit plný text záznamu